Skip to main content

Advertisement

SpringerLink
Log in

American Society of Hematology (ASH) 61st Annual Meeting: Orlando, FL, USA, 6–10 December 2019

  • Meeting Report
  • Published:
Targeted Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sanchez E, Smith EJ, Yashar MA, Patil S, Li M, Porter AL, et al. The role of B-cell maturation antigen in the biology and management of, and as a potential therapeutic target in multiple myeloma. Target Oncol. 2018;13:39–47.

    Article  Google Scholar 

  2. Berdeja JG, Alsina M, Shah N, Siegel DS, Jagannath S, Madduri D, et al. Updated results from an ongoing phase 1 clinical study of bb21217 anti-BCMA CAR T cell therapy. In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 927.

  3. Madduri D, Usmani SZ, Jagannath S, Singh I, Yudaire E, Yeh TM, et al. Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 577.

  4. Li C, Mei H, Hu Y, Guo T, Liu L, Jiang H, et al. A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial. In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 930.

  5. Costa LJ, Wong SW, Bermudez A, de la Rubia J, Mateos MV, Ocio EM, et al. First clinical study of the B-cell maturation antigen (BCMA) 2 + 1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 143.

  6. Cooper D, Madduri D, Lentzsch S, Jagannath S, Li J, Boyapati A, et al. Safety and preliminary clinical activity of REGN5458, an anti-BCMA × anti-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 3176.

  7. Lucs F, Woyach JA. Inhibiting Bruton’s tyrosine kinase in CLL and other B-cell malignancies. Target Oncol. 2019;14:125–38.

    Article  Google Scholar 

  8. Sharman JP, Banerji V, Fogliatto LM, Herishanu Y, Munir T, Walweska R, et al. ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (clb) in patients (pts) with treatment-naive chronic lymphocytic leukemia (CLL). In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 31.

  9. Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL). In: Presented at 2019 ASH Annual Meeting, December 7–10, 2019, Orlando, abstract 32.

  10. Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, et al. Efficacy and safety of zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): initial results from arm C of the Sequoia (BGB-3111-304) trial. In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 499.

  11. Cull G, Simpson D, Opat S, Burger JA, Trotman J, Marlton P, et al. Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): updated results from a phase 1/2 trial. Presented at: 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 500.

  12. Woyach J, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. In: Presented at 2019 ASH annual meeting, December 7–10, Orlando, abstract 4298.

  13. Allan JN, Patel K, Mato AR, Wierda WG, Ibarz JP, Choi MY, et al. Ongoing results of a phase 1B/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies. In: Presented at: 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 3041.

  14. Mato AR, Flinn IW, Pagel JM, Brown JR, Cheah CY, Coombs CC, et al. Results from a first-in-human, proof-of-concept phase 1 trial in pretreated B-cell malignancies for Loxo-305, a next-generation, highly selective, non-covalent BTK inhibitor. In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 501.

  15. Wei AH, Dӧhner H, Pocock C, Montesinos P, Afanayev B, Bombret H, et al. The QUAZAR AML-001 Maintenance Trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 in patients with acute myeloid leukemia (AML) in first remission. In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract LBA3.

  16. Brown PA, Ji L, Xu X, Devidas M, Hogan L, Borowitz MJ, et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as postreinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children’s Oncology Group Study AALL1331. In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract LBA1.

  17. Schuster SJ, Bartlett NL, Assouline S, Yoon SS, Bosch F, Sehn LH, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and Is active in treatment through multiple lines. In: Presented at 2019 ASH annual meeting, December 7–10, 2019, Orlando, abstract 6.

Download references

Acknowledgements

The author would like to thank the American Society of Hematology for the opportunity to attend this congress.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Martin Chopra

Authors
  1. Martin Chopra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Chopra.

Ethics declarations

Funding

No funding was received for the preparation of this meeting report.

Conflict of interest

Martin Chopra is a salaried employee of Adis/Springer, is responsible for the article content, and has no conflict of interest that might be relevant to the contents of this report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chopra, M. American Society of Hematology (ASH) 61st Annual Meeting: Orlando, FL, USA, 6–10 December 2019. Targ Oncol 15, 1–6 (2020). https://doi.org/10.1007/s11523-020-00699-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-020-00699-w

Search

Navigation